scholarly journals Telomerase activity assay for the diagnosis of malignant pleural effusion: A meta-analysis

2012 ◽  
Vol 4 (3) ◽  
pp. 487-492 ◽  
Author(s):  
YONG-CHUN SHEN ◽  
ZHEN-NI CHEN ◽  
TING YANG ◽  
LEI CHEN ◽  
TAO WANG ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Meta Analysis ◽  
Telomerase Activity ◽  
Activity Assay

scholarly journals Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis

2020 ◽  
Vol 14 (6) ◽  
pp. 645-654 ◽  
Author(s):  
Maged Hassan ◽  
Mohamed Gadallah ◽  
Rachel M Mercer ◽  
Elinor Harriss ◽  
Najib M. Rahman
Keyword(s):  
Systematic Review ◽  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Meta Analysis ◽  
Predictors Of Outcome

scholarly journals Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e87060 ◽  
Author(s):  
Huan Xia ◽  
Xiao-Juan Wang ◽  
Qiong Zhou ◽  
Huan-Zhong Shi ◽  
Zhao-Hui Tong
Keyword(s):  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Talc Pleurodesis

scholarly journals Diagnostic accuracy of endostatin for malignant pleural effusion: a systematic review and meta-analysis

2021 ◽  
Vol 6 ◽  
pp. 5-5
Author(s):  
Si-Yuan Yang ◽  
Ying Zhao ◽  
Xin-Ru Wang ◽  
Jing Wu ◽  
Dan-Ni Yang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pleural Effusion ◽  
Diagnostic Accuracy ◽  
Malignant Pleural Effusion ◽  
Meta Analysis

scholarly journals Intrathoracic infusion therapy of thymic peptides and chemical irritants for malignant pleural effusion: a meta-analysis of 24 randomized controlled trials

2020 ◽  
Author(s):  
zheng xiao ◽  
Cheng-Qiong Wang ◽  
Min He ◽  
You-Shu Shen ◽  
Xiao-Tian Zheng ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Randomized Controlled Trials ◽  
Malignant Pleural Effusion ◽  
Meta Analysis ◽  
Infusion Therapy ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Bias Risk ◽  
Chemical Irritants ◽  
Therapeutic Threshold

Abstract Background: To further determine the clinical efficacy and survival of intrathoracic infusion with TPs and chemical irritants and their therapeutic threshold and optimal control regimen to achieve a desired response in malignant pleural effusion (MPE). Methods: We collected all randomized controlled trials (RCTs) of TPs with chemical irritants from Chinese and English databases (from inception until September 2019), and performed a new meta-analysis following the PRISMA guidelines. We measured their bias risk, summarized data using meta-analysis, and evidence quality using the Grades of Recommendation Assessment, Development and Evaluation approach. Results: We collected 24 trials involving three TPs and platinum and 1,592 patients. Most trials had unclear bias risk. TPs with platinum significantly improved complete response [4.02 (3.12 to 5.18)] and quality of life [3.64 (2.34 to 5.66)], the 0.5-year overall survival (OS) rate [5.75 (3.02 to 10.92)], and 1-year OS rate [5.29, (1.71 to 16.36)], and reduced the treatment failure, myelosuppression, and gastrointestinal toxicity. For patients with moderate to large volume of pleural effusion, KPS score ≥50 to 60, or AST ≥3 months, the thymosin (200–300mg/time), thymopentin (2mg/time) or thymosin alpha 1 (3.2mg/time) with cisplatin (30–40mg/m 2 ), carboplatin (400mg/m 2 ), or oxaliplatin (100mg/m 2 ) are possible regimens for achieving a desired success, and low failure. Most results were robust and moderate quality. Conclusion: The moderate evidence suggests that the TPs with platinum is beneficial to the patient with MPE, and provides evidence for the therapeutic threshold and possible regimens that may achieve a desired success and reduce the failure.

Sign in / Sign up

Export Citation Format

Share Document